

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]

Final Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Taiho Pharma Europe (futibatinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • AMMF – The Cholangiocarcinoma Charity • Black Health Agency for Equality • British Liver Trust • Cancer Black Care • Cancer Equality • Cancer52 • GUTS UK • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Liver4Life • Macmillan Cancer Support • Maggie’s Centres • Marie Curie • Pelican Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • Together Support Group <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland • British Association for the Study of the Liver (BASL) • British Association of Surgical Oncology • British Geriatrics Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Welsh Government • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Hospira UK (fluorouracil, oxaliplatin) • Incyte Biosciences (pemigatinib) • Medac (folinic acid, fluorouracil, oxaliplatin) • Ranbaxy, a Sun Pharmaceutical company (oxaliplatin) • Seacross Pharmaceuticals (oxaliplatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane UK • Cochrane Upper Gastrointestinal and Pancreatic Diseases Group

Final stakeholder list for the evaluation of futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]

Issue date: November 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Institute of Radiology • British Oncology Pharmacy Association • British Psychosocial Oncology Society • British Society of Gastroenterology • British Society of Interventional Radiology • Cancer Research UK • Cholangiocarcinoma-UK • Primary Care Society for Gastroenterology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Foundation for Liver Research • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of futibatnib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]

Issue date: November 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

All non-company consultees are invited to submit a statement, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Non-company consultees are invited to submit statements relevant to the group they are representing.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.